FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Irlbeck

Research Profile

Chemicals & Drugs

Living Beings

Disorders

HIV Infections

Physiology

Co-author Network

Publications

TOP 3
Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Jesús Saavedra-Lozano; José Tomás Ramos; Francisco Sanz; M Luisa Navarro; Maria Isabel de José; Pablo Martín-Fontelos; Ma José Mellado; Juan A León Leal; Cecilia Rodriguez; Isabel Luque; Samuel J Madison; David Irlbeck; E Randall Lanier; Octavio Ramilo
Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
John A Bartlett; Judy Johnson; Gisela Herrera; Nestor Sosa; Allan Rodriguez; Qiming Liao; Sandy Griffith; David Irlbeck; Mark Shaefer
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Irlbeck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
PLoS medicine 2008;5(7):e158.
2006: Jesús Saavedra-Lozano; José Tomás Ramos; Francisco Sanz; M Luisa Navarro; Maria Isabel de José; Pablo Martín-Fontelos; Ma José Mellado; Juan A León Leal; Cecilia Rodriguez; Isabel Luque; Samuel J Madison; David Irlbeck; E Randall Lanier; Octavio Ramilo
Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
The Pediatric infectious disease journal 2006;25(12):1142-52.
2006: John A Bartlett; Judy Johnson; Gisela Herrera; Nestor Sosa; Allan Rodriguez; Qiming Liao; Sandy Griffith; David Irlbeck; Mark Shaefer
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Journal of acquired immune deficiency syndromes (1999) 2006;43(3):284-92.
2006: Allan Rodriguez; Christina Hill-Zabala; Louis Sloan; Thomas Jefferson; Linda Yau; Maria Watson; David Irlbeck; Mark Shaefer
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Journal of acquired immune deficiency syndromes (1999) 2006;41(1):127-9.
2004: E Randall Lanier; N Givens; Chris Stone; Philip Griffin; Diana M Gibb; S Walker; Margaret Tisdale; David Irlbeck; M Underwood; Marty St Clair; Mounir Ait-Khaled
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
HIV medicine 2004;5(6):394-9.
2003: Terri Watkins; Wolfgang Resch; David Irlbeck; Ronald Swanstrom
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.
Antimicrobial agents and chemotherapy 2003;47(2):759-69.
2000: Nancy L Davis; IJ Caley; K W Brown; MR Betts; David Irlbeck; K M McGrath; Mary J Connell; David C Montefiori; Jeffrey Frelinger; Ronald Swanstrom; Philip R Johnson; Robert E Johnston
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.
Journal of virology 2000;74(1):371-8.
1999: M Vaillancourt; David Irlbeck; T Smith; R W Coombs; Ronald Swanstrom
The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance.
AIDS research and human retroviruses 1999;15(4):355-63.
1997: IJ Caley; MR Betts; David Irlbeck; Nancy L Davis; Ronald Swanstrom; Jeffrey Frelinger; Robert E Johnston
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
Journal of virology 1997;71(4):3031-8.